X4 Pharmaceuticals (XFOR) Capital Expenditures (2017 - 2025)

X4 Pharmaceuticals (XFOR) has reported Capital Expenditures for 9 consecutive years, with $500000.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Capital Expenditures changed N/A year-over-year to $500000.0; the trailing twelve-month figure through Dec 2025 stood at $500000.0 (down 85.71% YoY), and the FY2025 full-year result was $500000.0, down 85.71% from the prior year.
• Capital Expenditures eased to $500000.0 in Q4 2025 per XFOR's latest filing, from $3.4 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $3.4 million in Q2 2024 and bottomed at $8000.0 in Q2 2023.
• Historically, Capital Expenditures has averaged $318533.3 across 5 years, with a median of $34000.0 in 2022.
• The sharpest annual moves came in 2021 and 2024: Capital Expenditures slumped 98.66% in 2021, then jumped 42912.5% in 2024.
• Over 5 years, Capital Expenditures stood at $13000.0 in 2021, then surged by 161.54% to $34000.0 in 2022, then gained by 2.94% to $35000.0 in 2023, then surged by 9731.43% to $3.4 million in 2024, then tumbled by 85.47% to $500000.0 in 2025.
• According to Business Quant data, Capital Expenditures over the past three periods registered $500000.0, $3.4 million, and $59000.0 for Q4 2025, Q2 2024, and Q1 2024 respectively.